Global Glycomics/Glycobiology Market Report 2022: Glycomics Applications in Precision Medicine Presents Lucrative Opportunities – ResearchAndMarkets.com

Global Glycomics/Glycobiology Market Report 2022: Glycomics Applications in Precision Medicine Presents Lucrative Opportunities - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Glycomics/Glycobiology Market by Product (Enzymes (Glycosidases, Transferases), Instruments (Mass Spectrometry, Chromatography, Arrays), Kits, Carbohydrates, Reagents), Application (Drug Discovery, Diagnostics), End-user, and Region – Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The global glycomics/glycobiology market is projected to reach USD 3.7 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 15.5% during the forecast period. The growth of the market is projected to be driven by factors such as increasing number of collaboration and partnership by prominent players in the market for improved glycan analysis, emerging use of glycans as biomarker, and technological advancement.

The enzyme segment grabbed the highest share of the glycomics/glycobiology market in 2022

Based on product, the glycomics/glycobiology market is segmented into enzymes, kits, instruments, carbohydrates and reagents & chemicals. In 2022, the highest share of the market is held by enzyme segment. This is owing to the consumable nature of enzymes and wide application in R&D activities.

The drug discovery & development segment accounts for the largest share of the application segment in glycomics/glycobiology market

In 2021, the drug discovery & development segment accounted for the largest share of the market. The largest share of this segment is due to the increasing application of glycomics in drug discovery and development and rising R&D investment by pharmaceutical & biotechnology.

North America: Accounted for the largest share in the glycomics/glycobiology market

The North America is estimated to be the fastest-growing segment of the market, owing to the increasing presence of pharmaceutical and biotechnology companies, improved healthcare infrastructure and more increasing investments by companies in glycobiology research. In this region, US reports the fastest growth of the glycomics/glycobiology market.

Market Dynamics

Market Dynamics

Drivers

Emergence of Glycans as Biomarkers

Technological Advancements in Glycan Analysis

Increasing R&D Expenditure and Funding

Collaborations and Partnerships

Increasing Number of Cancer Cases Worldwide

Restraints

High Cost of Glycobiology Products and Tools

Opportunities

Glycomics Applications in Precision Medicine

Challenges

Lack of Skilled Workforce

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Glycomics/Glycobiology Market, by Product

7 Glycomics/Glycobiology Market, by Application

8 Glycomics/Glycobiology Market, by End-user

9 Glycomics/Glycobiology Market, by Region

10 Competitive Landscape

11 Company Profiles

12 Appendix

Companies Mentioned

Agilent Technologies

AMSBIO

Asparia Glycomics

Bio-Techne

Bruker Corporation

CD BioGlyco

Chemily Glycoscience

Danaher Corporation

GlycoDiag

Glycomix

Glyxera GmbH

IEC S.p.A.

Kode Biotech Limited

Lectenz Bio

Ludger

Merck KGaA

New England Biolabs

Promega Corporation

Raybiotech Life

Shimadzu Corporation

Sumitomo Bakelite

Takara Bio

Thermo Fisher Scientific

Waters Corporation

Z Biotech, LLC

For more information about this report visit https://www.researchandmarkets.com/r/jsurml

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.